Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the safest dose level of an approved drug, carfilzomib,
in solid tumors when given over a different period of time than normally used. The study will
also use markers in blood from routine blood draws to help check the levels of the drug.
Lastly, the study will check how well this drug works with regards to keeping cancer cells
from growing with the new time frame of delivery.